Monday, April 25, 2005 3:49:05 AM ET Dow Jones Newswires
0744 GMT [Dow Jones] Morgan Stanley surprised by Shire Pharmaceuticals (SHPGY) share price drop on Transkaryotic Therapies acquisition. Says analysis suggests deal "could be highly value enhancing." Notes deal will strengthen Shire's existing renal and hematology product offering, and that all of Transkaryotic's products have "long periods of exclusivity, a feature that Shire's product portfolio has historically lacked." Is advisor to Shire, thus no rating. Shire +0.6% at 542p.